<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8"/>
  <meta name="viewport" content="width=device-width, initial-scale=1"/>
  <title>LiquidMammo™ | Breast cancer screening, reimagined</title>

  <!-- SEO -->
  <meta name="description" content="LiquidMammo is a microRNA-based liquid biopsy for early breast cancer detection—non-invasive, clinician-ordered, and designed to complement imaging.">
  <meta name="keywords" content="breast cancer screening, microRNA test, liquid biopsy, early detection test, dense breasts screening, mammography complement, molecular detection">

  <!-- Styles -->
  assets/css/styles.css

  <!-- Favicon -->
  favicon.png
</head>

<body>

<!-- =========================
     HEADER
========================== -->
<header>
  <div class="container">
    <nav>

      <!-- BRAND (logo + wordmark) -->
      <div class="brand">
        <img src="assets/logos/liquidmammo-logo.png" alt="LiquidMammo logo"/>
        <strong>LiquidMammo™</strong>
      </div>

      <!-- NAVIGATION -->
      <div class="nav-links">
        <a href="how-it-works.html">How It Works</a>
        <a href="science.html">Science</a>
        <a href="evidence.html">Evidence</a>
        <a href="patients.html">Patients</a>
        <a href="clinicians.html">Clinicians</a>
        <a href="biobank.html">Biobank</a>
        <a href="pricing.html">Pricing</a>
        <a href="contact.html">Contact</a>
        <a href="privacy.html">Privacy</a>
        <a href="about.html">About</a>
      </div>

    </nav>
  </div>
</header>


<!-- =========================
     HERO
========================== -->
<section class="hero">
  <div class="container grid-2">

    <!-- TEXT SIDE -->
    <div>
      <span class="eyebrow">Non‑invasive • Clinician‑ordered • Density‑aware</span>

      <h1>Breast cancer screening, reimagined.</h1>

      <p class="kicker">A microRNA blood test designed to complement imaging.</p>

      <p class="small">
        Early molecular changes often precede structural findings on mammography. LiquidMammo provides a
        non‑invasive signal that strengthens clinical decision‑making—especially where breast density limits
        traditional imaging performance.
      </p>

      <div class="cta-row">
        <a class="btn" href="patients.html#join">Join Early Access</a>
        <a class="btn secondary" href="clinicians.html#enroll">Clinician Enrollment</a>
      </div>

      <p class="notice">
        Regulatory: LiquidMammo is being developed as a <strong>CLIA Laboratory Developed Test (LDT)</strong>; not yet FDA‑cleared/approved.
      </p>
    </div>

    <!-- IMAGE SIDE -->
    <div>
      <img
        src="https://images.unsplash.com/photo-1606205685561-2038323a6472?auto=format&fit=crop&w=1200&q=80"
        alt="Clinician handling blood tubes in a molecular diagnostics laboratory"
      />
    </div>

  </div>
</section>


<!-- =========================
     WHY IT MATTERS
========================== -->
<section class="panel-light section">
  <div class="container grid-3">

    <div class="card-mini">
      <h4>Dense breasts challenge mammography</h4>
      <p class="small">
        Sensitivity drops to ~61% in extremely dense tissue. Interval cancers are more common. A molecular
        complement may reduce misses.
      </p>
    </div>

    <div class="card-mini">
      <h4>Earlier biological signal</h4>
      <p class="small">
        microRNA shifts can occur before imaging-visible lesions. Combining biology + imaging strengthens
        screening performance.
      </p>
    </div>

    <div class="card-mini">
      <h4>Addresses real‑world variability</h4>
      <p class="small">
        Mammographic detection varies by density, age, equipment, and reader. A standardized molecular layer
        improves consistency.
      </p>
    </div>

  </div>
</section>


<!-- =========================
     CLINICAL CONTEXT
========================== -->
<section class="section">
  <div class="container">

    <h2>Clinical context</h2>

    <div class="grid-3">

      <div class="stats-card">
        <ul class="list-tight">
          <li><strong>1 in 8</strong> cancers missed by mammography overall</li>
          <li><strong>Higher interval cancer rates</strong> in dense breasts</li>
          <li><strong>~50–60%</strong> false‑positive probability over 10 years</li>
        </ul>
      </div>

      <div class="stats-card">
        <ul class="list-tight">
          <li><strong>~61% sensitivity</strong> in extremely dense tissue</li>
          <li><strong>2–3 per 1,000</strong> cancers detected in younger women</li>
          <li><strong>Lower participation</strong> when imaging alone is used</li>
        </ul>
      </div>

      <div class="card note-card">
        <p class="small">
          LiquidMammo complements—not replaces—imaging. By layering molecular and imaging signals, clinicians can
          contextualize risk, reduce uncertainty, and improve consistency.
        </p>
      </div>

    </div>

  </div>
</section>


<!-- =========================
     HOW IT WORKS
========================== -->
<section class="panel-light section">
  <div class="container">

    <h2>How it works</h2>

    <div class="grid-3">

      <div class="card-mini">
        <h4>1 — Ordered by clinician</h4>
        <p class="small">Clinician‑initiated blood draw at routine visit; no preparation needed.</p>
      </div>

      <div class="card-mini">
        <h4>2 — microRNA profiling</h4>
        <p class="small">A proprietary multi‑marker panel quantifies tumor‑associated microRNA dysregulation.</p>
      </div>

      <div class="card-mini">
        <h4>3 — Actionable report</h4>
        <p class="small">Results delivered with density‑aware interpretation and subgroup context.</p>
      </div>

    </div>

  </div>
</section>


<!-- =========================
     FOOTER
========================== -->
<footer>
  <div class="container footer-grid">

    <div>
      <strong>LiquidMammo™</strong><br>
      A test developed by MultiOmics Inc.
      <p class="footer-note">
        MultiOmics Inc. is headquartered in Washington, DC, and operates out of LabCentral, Cambridge, MA.
      </p>
    </div>

    <div class="footer-logo">
      <img src="assets/logos/multiomics-logo.png" alt="MultiOmics logo"/>
      <div class="footer-note" style="line-height:1.2">
        Developed by<br>MultiOmics Inc.
      </div>
    </div>

  </div>

  <div class="container footer-note" style="margin-top:20px;">
    © <script>document.write(new Date().getFullYear())</script> MultiOmics Inc. •
    <a href="privacy.html">Privacy & Compliance</a> •
    <a href="contact.html">Order / Kits</a>
  </div>
</footer>

</body>
</html>








